| ATC code M: Musculo-skeletal system |
|---|
|
| Other ATC codes |
ATC code M Musculo-skeletal system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QM.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code M". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QM". WHO Collaborating Centre for Drug Statistics Methodology.
| Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
|---|---|
| pyrazolones / pyrazolidines | |
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
| Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
| Specific antirheumatic products / DMARDs (M01C) | |
|---|---|
| Quinolines | |
| Gold preparations | |
| Other | |
| |
| Topical products for joint and muscular pain (M02) | |||||||
|---|---|---|---|---|---|---|---|
| Anti-inflammatory preparations, non-steroids |
| ||||||
| Capsaicin derivatives | |||||||
| Other | |||||||
| Drugs used for gout (M04) | |||||
|---|---|---|---|---|---|
| Uricosurics |
| ||||
| Xanthine oxidase inhibitors |
| ||||
| Mitotic inhibitors | |||||
| Other | |||||
| |||||
| Drugs for treatment of bone diseases (M05) | |
|---|---|
| Bisphosphonates | |
| Bone morphogenetic proteins | |
| Other |
|
| Other drugs for disorders of the musculo-skeletal system (M09) | |
|---|---|
| Quinine and derivatives | |
| Enzymes | |
| Gene therapies | |
| Antisense oligonucleotides | |
| Glucocorticoids | |
| Histone deacetylase inhibitors | |
| Other | |
| |
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |